US Broker Ratings

Bicycle Therapeutics plc (BCYC) Stock Analysis: Revealing a Potential 147.67% Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biotechnology firm headquartered in Cambridge, UK, is drawing significant attention from the investment community. Operating within the healthcare sector, the company is focused..

Evolus, Inc. (EOLS): Analyzing a 129% Potential Upside with a Strong Analyst Consensus

Evolus, Inc. (NASDAQ: EOLS), a dynamic player in the healthcare sector, is capturing investor interest with a compelling narrative of growth potential. Specializing in the performance beauty market, Evolus focuses..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 60% Potential Upside in the Biotech Sector

Immunome, Inc. (NASDAQ: IMNM) stands out in the biotechnology sector with its bold strides in oncology therapeutics, particularly in antibody-drug conjugates. Despite a 0.05% dip in its current price to..

Delcath Systems, Inc. (DCTH) Stock Analysis: Aiming for an 89.80% Upside in the Medical Device Sector

Delcath Systems, Inc. (NASDAQ: DCTH) is catching the eye of investors with its significant potential upside of 89.80%, as reflected in recent analyst ratings. With a current market cap of..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 67.87% Potential Upside

Relay Therapeutics, Inc. (NASDAQ: RLAY) stands out in the biotechnology sector with promising growth potential, despite the challenges highlighted by its recent financial performance. As a clinical-stage precision medicines company,..

Talkspace, Inc. (TALK) Stock Analysis: Exploring the 18.73% Potential Upside for Investors

Talkspace, Inc. (TALK), a leader in virtual behavioral healthcare, is gaining attention from investors as it positions itself within the rapidly growing telehealth sector. With a market capitalization of $867.72..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Navigating a 32% Potential Upside in the Rare Disease Market

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is steadily capturing the attention of investors with its focused approach in the healthcare sector, specifically targeting the niche market of treatments for rare diseases...

Valneva SE (VALN) Stock Analysis: Exploring a Potential 119.87% Upside in the Biotechnology Sector

Valneva SE (NASDAQ: VALN), a French biotechnology company specializing in the development of vaccines for infectious diseases, presents a compelling opportunity for investors with its robust product pipeline. Despite recent..

Geron Corporation (GERN) Stock Analysis: Exploring a 173.97% Potential Upside in Innovative Cancer Therapies

Geron Corporation (NASDAQ: GERN) is capturing investor attention with its promising potential upside of 173.97%, as highlighted by recent analyst ratings. This commercial-stage biopharmaceutical company, headquartered in Foster City, California,..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 93.91% Potential Upside for Investors

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, is drawing significant attention from investors with an impressive potential upside of 93.91%, according to recent analyst ratings. Headquartered in Lexington,..

InMode Ltd. (INMD) Stock Analysis: Exploring the 16.74% Potential Upside in the Medical Devices Sector

Investors with a keen interest in the healthcare sector, particularly in medical devices, may find InMode Ltd. (NASDAQ: INMD) an intriguing prospect. Headquartered in Yokne’am, Israel, InMode is a key..

Sionna Therapeutics, Inc. (SION): Investor Outlook on its Promising 16.83% Upside Potential

Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company, is capturing investor attention with its ambitious pipeline focused on treating cystic fibrosis (CF). As a trailblazer in the biotechnology industry, Sionna..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Eyeing a 45.94% Upside Potential in the Biotech Sector

ArriVent BioPharma, Inc. (NASDAQ: AVBP), a clinical-stage biopharmaceutical company, is capturing the attention of investors with its promising pipeline and significant upside potential. Specializing in the development and commercialization of..

Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a Potential 93% Upside in Medical Devices

Beta Bionics, Inc. (NASDAQ: BBNX) is capturing the attention of investors with its innovative approach in the healthcare sector, specifically within the medical devices industry. The company is at the..

Immatics N.V. (IMTX) Stock Analysis: Potential 68% Upside Amid Strategic Collaborations and Innovative Cancer Therapies

Immatics N.V. (NASDAQ: IMTX), a promising player in the biotechnology sector, is capturing investor attention with its cutting-edge approach to cancer treatment. Headquartered in Tübingen, Germany, this clinical-stage biopharmaceutical company..

Rocket Pharmaceuticals (RCKT) Investor Outlook: Exploring a 140.90% Potential Upside in Genetic Therapies

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a promising player in the biotechnology sector, leveraging cutting-edge genetic therapies aimed at treating rare and devastating diseases. With a current market capitalization of..

HealthStream, Inc. (HSTM) Stock Analysis: Unveiling a 35.94% Potential Upside in Health Information Services

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the health information services industry, presents an intriguing opportunity for investors looking for growth in the healthcare sector. With a market capitalization..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating a 22% Potential Upside Amidst a Challenging Landscape

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector specializing in diagnostics and research, offers a mixed bag of opportunities and challenges for investors. Currently trading at..

AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking a 21.51% Upside Potential Amid Robust Revenue Growth

AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company that has caught the attention of investors with its focus on delivering cutting-edge immunology therapeutics for autoimmune and inflammatory diseases. With..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring a 32% Potential Upside in Biotech Innovation

Bicara Therapeutics Inc. (NASDAQ: BCAX), a promising player in the biotechnology sector, is garnering attention from investors eager to explore the potential of its innovative bifunctional therapies for solid tumors...

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds